Chinese pharmaceutical company Sinopharm on Wednesday announced that its vaccine has nearly 80% efficacy and is seeking market approval from authorities.
It was developed by China National Biotech Group (CNBG), a subsidiary of the state-owned Sinopharm.
The vaccine has 79.34% efficacy and around 99.52% antibody positive conversion rate, the Beijing Biological Products Institute said in a statement.
It added that interim results of Phase 3 clinical trials, which are underway in a number of countries, on its inactivated vaccine showed that “the vaccine can trigger high-titer coronavirus antibodies after two injections.”
Earlier this month, the UAE officially approved Sinopharm’s experimental vaccine, saying it has 86% efficacy.
China has a total of six vaccine candidates in the final stage of trials, including the ones developed by Sinopharm and Sinovac, which were approved for emergency use in the country this summer.
Source: Anadolu Agency